Efficacy and safety of glecaprevir and pibrentasvir in chronic hepatitis C patients with hemodialysis

Efficacy and safety of glecaprevir and pibrentasvir in chronic hepatitis C patients with hemodialysis - Efficacy of glecaprevir and pibrentasvir in chronic hepatitis C patients with hemodialysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029781

Enrollment

Registered

2017-11-21

Start date

2017-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C with hemodialysis

Interventions

glecaprevir 300mg and daclatasvir 120mg daily for 8 or 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Chronic hepatitis or cirrhosis patients (2) Patients with hemodialysis (3) Patients with 20 years of age and older

Exclusion criteria

Exclusion criteria: (1) Decompensated cirrhosis, Liver failure (2)patients with hepatic cell carcinoma (3) Co-infection with hepatitis B virus Co-infection with anti- humanimmunodeficiency virus

Design outcomes

Primary

Measure	Time frame
Sustained virologic response rate at 12 weeks post-treatment	—

Secondary

Measure	Time frame
Safety The factor associated with sustained virologic response Emergence of drug-resistant virus Cumulative incidence of hepatocellular carcinoma	—

Countries

Japan

Contacts

Public ContactHaruki Uojima

Kitasato University School of Medicine Department of Gastroenterology

kiruha@kitasato-u.ac.jp+81-42-778-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026